NCT07472140RecruitingPhase 2/3
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.
Source: ClinicalTrials.gov · Last updated 16 Mar 2026
Brief summary (registry, in English)
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 2 Mar 2026
- Start date
- 1 Jul 2025
- Primary completion date
- 30 Jun 2033
- Lead sponsor
- N.N. Alexandrov National Cancer Centre
- Diseases
- Ovarian cancer
- NCT number
- NCT07472140
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 120
- From 1 Jul 2025 to the primary completion date, 30 Jun 2033
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of another active malignant invasive neoplasm.
- Disease progression during treatment.
Other
- Pregnancy or lactation period.
Who the study is looking for
- Age ≥18-≤75 years.
- Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
- Presence of homologous recombination deficiency (HRD).
- No contraindications to chemotherapy, or bevacizumab.
- Signed informed consent to participate in the study.
Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| N.N. Alexandrov National Caner Centre Coordinator of this site? Confirm its status | Minsk | Belarus | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.